Everything moves slower in Alzheimer's research than in cancer
For nearly two decades, a team at ETH Zurich has been quietly pursuing one of medicine's most elusive questions: how to slow the erosion of the self that Alzheimer's disease brings. Their answer, a molecule called Compound 10, works not by targeting the usual suspects but by interrupting a destructive cycle deep within the cell's own energy machinery. In mouse models, it preserved neurons, reduced the hallmark deposits of the disease, and extended survival — a result that now carries the work from foundational science into the long, uncertain passage toward human treatment.
- Dementia claims tens of millions of lives and remains without a cure, making every credible new mechanism a matter of profound urgency.
- ETH Zurich researchers discovered that a rogue, inactivated form of the GRK2 enzyme accumulates in Alzheimer's brains, clogs mitochondria, and fuels a self-reinforcing cycle of cellular destruction.
- Compound 10 broke that cycle in mice — restoring mitochondrial function, cutting beta-amyloid deposits, and keeping neurons alive long enough to hint at something genuinely new.
- The compound's effects reached beyond the brain, improving heart function and even slowing visible signs of aging in treated animals, suggesting a broader cellular impact.
- A patent has been filed and drug development is now underway, though the road from mouse model to human clinic remains long, expensive, and uncertain.
Dementia is the seventh leading cause of death worldwide, and Alzheimer's accounts for the majority of those cases. For nearly twenty years, a team led by molecular pharmacologist Ursula Quitterer at ETH Zurich has been working toward a new kind of answer.
The research began with an unlikely source: brain tissue samples from tumor surgeries at a Cairo hospital, sent to Quitterer by a physician colleague. Comparing tissue from people with and without dementia, her team identified an enzyme called GRK2 as a central player in the disease's progression. In healthy brains, GRK2 helps nerve cells respond to stress and signals. But in Alzheimer's patients, a metabolically inactivated form of the enzyme accumulates in large quantities, clumping into aggregates that lodge inside mitochondria — the cell's power generators — and block their function. The resulting energy deficit stresses neurons and, crucially, promotes the production of beta-amyloid, the protein long associated with Alzheimer's. More beta-amyloid creates more inactive GRK2, and the cycle deepens.
To break it, the team synthesized a series of chemical compounds and tested them in cell cultures and aging mice. Compound 10 proved most effective at preventing GRK2 from aggregating. In treated mice, mitochondria recovered, beta-amyloid deposits fell, and neurons survived. The benefits extended to heart function and general aging — treated animals even developed fewer gray hairs, a small but telling sign of broader cellular health.
The research moved slowly by necessity: Alzheimer's is an age-related disease, and each experiment with elderly mice required up to two years before results could guide the next step. Quitterer noted that the field moves far more deliberately than cancer research, a pace that reflects the disease's complexity rather than any lack of urgency.
What distinguishes Compound 10 is not only that it worked, but that it works differently from any existing Alzheimer's treatment. By targeting GRK2 aggregation, the team has opened a new therapeutic pathway — one that Quitterer envisions might eventually be combined with other medications to improve patients' quality of life. A patent has been filed, and drug development has begun. The clinic remains years away, but the distance is now measurably shorter.
Dementia kills more people than most of us realize. The World Health Organization counts it as the seventh leading cause of death globally, and it ranks among the top sources of disability and dependency in older adults. Alzheimer's disease accounts for between 60 and 70 percent of those cases. For nearly two decades, a team at ETH Zurich has been working on a potential answer.
The researchers, led by Ursula Quitterer, a molecular pharmacology professor, developed a compound called Compound 10. In mouse trials, it slowed the progression of Alzheimer's by reducing the death of neurons and extending the animals' survival. The work has now completed its foundational phase, and the team has filed for a patent. The next phase is drug development—the long, uncertain path from laboratory success to human treatment.
The project's origins trace back to brain tissue samples collected during tumor surgeries at Ain Shams University Hospital in Cairo. A physician and colleague sent these samples to Quitterer—tissue from both people with dementia and people without it. By analyzing the molecular makeup of that tissue and running experiments in mice, Quitterer's team identified an enzyme called GRK2 as central to dementia's progression. The findings were published in Cell Reports Medicine.
GRK2 is a regulatory protein that helps cells respond to signals, stress, and strain. It works in many organs, including the brain, where it supports nerve cell function. But the researchers found something troubling: in brain tissue from dementia patients, GRK2 exists in two forms—one normal and functional, the other inactivated by the cell's own metabolism. In the brains of people with Alzheimer's, the inactive form appeared in large quantities. The same pattern showed up in mouse models of the disease. These inactive GRK2 molecules clump together, forming aggregates that deposit inside mitochondria—the cell's power plants—and damage them. As Quitterer explained, these aggregates block the mitochondria's pores, reducing the energy they can supply and creating stress within the cell.
The inactive GRK2 also promotes production of beta-amyloid, a protein fragment long suspected as a primary driver of Alzheimer's. The researchers identified a vicious cycle: beta-amyloid puts pressure on neurons, and that pressure triggers the formation of more inactive, aggregated GRK2. To break the cycle, they synthesized several chemical compounds and tested them in cell cultures and mice. Compound 10 proved most effective at preventing GRK2 molecules from clumping together.
When Compound 10 blocked GRK2 aggregation, mitochondria functioned better, beta-amyloid deposits decreased, and neurons maintained their function and avoided cell death. The effects extended beyond the nervous system. Treated mice showed improvements in heart function and aging processes. The researchers even noted that treated animals developed fewer gray hairs in old age—a small detail that hints at the compound's broader impact on cellular health.
The research took nearly two decades because Alzheimer's is an age-related disease. The team worked with mice aged 1.5 to 2 years, and each experiment at that age required 1.5 to 2 years to produce results that could guide the next phase. Quitterer acknowledged the pace: Alzheimer's research moves far more slowly than cancer research, she said. But that slowness reflects the disease's complexity and the care required to understand it.
What matters most about this work is not just that Compound 10 worked in mice, but that it works through a mechanism different from existing Alzheimer's drugs. By targeting GRK2, the team has opened a new therapeutic door. Quitterer suggested that Compound 10 might one day be used alongside other medications to improve patients' quality of life. For now, the compound moves from the laboratory into the next phase of development—closer to the clinic, but still years away from the people who need it most.
Citas Notables
The aggregates of GRK2 block the pores of mitochondria, reducing the energy they can supply and creating stress within cells— Ursula Quitterer, ETH Zurich
It took so long simply because everything moves much slower in Alzheimer's research than in cancer research, for example— Ursula Quitterer, ETH Zurich
La Conversación del Hearth Otra perspectiva de la historia
Why did this research take so long? Twenty years seems extraordinary.
Because you're studying a disease of aging in aged mice. Each experiment takes as long as the disease does to show itself. You can't rush biology.
And the breakthrough—this GRK2 enzyme—how did they find it?
They started with actual human brain tissue from Cairo, from people with and without dementia. They compared them molecularly. That's how you see what's different.
So Compound 10 stops the protein from clumping?
Yes. The inactive GRK2 forms aggregates that damage the mitochondria—the cell's battery. Block the clumping, the battery works again, the neuron survives.
But it's still just mice.
It is. But the mechanism is novel. Existing drugs work one way. This works another. That matters because combination therapy might eventually do what neither could alone.
What surprised you most in the results?
That the effects weren't limited to the brain. Heart function improved. Aging processes slowed. Even the gray hair finding—it suggests the compound touches something fundamental about cellular aging itself.
How far away is a human trial?
They just filed the patent. Drug development from here is typically years. But they've cleared the hardest part: proving the target exists and that blocking it works.